Ellipses Pharma Presents Design of Newly Initiated Phase 1/2a Trial of Vosilasarm (EP0062) at SABCS

2022-12-05

临床1期

LONDON--(BUSINESS WIRE)-- Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, will present a “Trial in Progress” poster detailing the design of a Phase 1/2 trial of vosilasarm (EP0062) in advanced breast cancer at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas on Tuesday, 6 December from 5:00pm to 6:15pm CST. Vosilasarm is a selective androgen receptor modulator (SARM) under development for the potential treatment of advanced breast cancer. This study is designed to further extend the evaluation of vosilasarm as a potential therapy for AR+/HER2–/ER+ advanced breast cancer, with the primary aim of identifying a recommended phase 2 dose (RP2D). Recruitment has commenced and the study will recruit up to 130 patients globally. Presentation details Title A phase 1/2 study to evaluate the safety and efficacy of EP0062, an oral Selective Androgen Receptor Modulator (SARM), for the treatment of AR+/HER2-/ER+ advanced breast cancer Presenter Professor Elgene Lim, Institute of Medical Research, University of New South Wales, Sydney, Australia; Abstract number OT1-02-02 Date and time Tuesday December 6, 2022; 5:00 PM - 6:15 PM Session name Trial in Progress Session Location Henry B. González Convention, San Antonio, Texas Professor Hendrik-Tobias Arkenau, Global Head of Drug Development and Chief Medical Officer at Ellipses, said: “Developing promising assets at speed is fundamental to the work of Ellipses, and we are excited to be presenting this ongoing study at such an important scientific conference. We look forward to presenting further details on this trial, including results, in the future.” Dr Rajan Jethwa, CEO of Ellipses, said: “The initiation of this trial for vosilasarm is another key milestone towards our goal of accelerating the development of promising cancer drugs. I am excited by the potential across our pipeline to make available much-needed drugs for patients with cancer.” About vosilasarm / EP0062 Vosilasarm is an oral, non-steroidal, SARM currently being developed for the treatment of AR+/HER2-/ER+ advanced breast cancer. The efficacy and safety of vosilasarm has previously been investigated in a small Phase 1 clinical trial of AR+/HER2–/ER+ advanced breast cancer, and was demonstrated to have acceptable tolerability with preliminary evidence of clinical efficacy (LoRusso et al. Clinical Breast Cancer 2022 22;1 67-77). About AR+/HER2–/ER+ advanced breast cancer Despite recent progress, advanced ER+/HER2- breast cancer remains an area of high unmet medical need. It is estimated that 75-90% of advanced ER+ breast cancers are androgen receptor (AR) positive. It has been established that the AR acts as a tumour suppressor in multiple contexts of ER+ breast cancer, including where resistance to current endocrine-based regimens develops (Hickey et al. Nature Medicine 2021 27; 310-320). This provides the rationale for evaluating vosilasarm, an AR agonist, as a potential treatment strategy. About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer medicines and treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimize the time it takes to advance lead products through clinical trials and reach patients. For more information, please visit ellipses.life View source version on businesswire.com: Contacts Ellipses Pharma Ltd Suzanne Wood media@ellipses.life Source: Ellipses Pharma Limited View this news release online at:

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构